Reducing Cardiovascular Risk With PCSK9 Inhibitors in Patients With Recent Acute Coronary Syndromes

In this program, lipid expert Dr. James Underberg will describe best practices with PCSK9 inhibitors in patients who have experienced an ACS.

Cholesterol guidelines recommend nonstatin, LDL-C-lowering therapies in very high risk ASCVD patients if LDL-C goals are not achieved (ESC/EAS dyslipidemia guideline) or if LDL-C is above a specific threshold of 70 mg/dL (AHA/ACC cholesterol guideline). Unfortunately, a substantial number of patients with ASCVD do not achieve LDL-C targets, and nonstatin, LDL-C-lowering therapies are underutilized. Therefore, patients such as those who have experienced an acute coronary syndrome (ACS) remain at increased risk for another major cardiovascular event. Patients with a recent ACS are especially vulnerable to a recurrent cardiovascular event. Nonstatin, LDL-C-lowering therapy with PCSK9 inhibitors and ezetimibe has demonstrated reductions in cardiovascular risk after an ACS. PCSK9 inhibitors have demonstrated robust LDL-C lowering to very low LDL-C levels, with no increase in adverse safety events and with additional cardiovascular risk reduction. Analyses of cardiovascular outcome trial data with PCSK9 inhibition have indicated particularly potent cardiovascular risk reduction in patients with a recent ACS; utilizing PCSK9 inhibitors in these patients enables clinicians to greatly improve their patients ' clinical outcomes. Significant LDL-C reductions, rapid LDL-C goal attainment, and safety have been observed in very early (in-hospital) use of PCSK9 inhibitors. Lipid expert Dr. James Underberg will describe best practices with PCSK9 inhibitors in patients who have experienced an ACS in this educational initiative which will be streamed live to Dr. Underberg’s Twitter handle @LipidDoc. 

Login to your Account